An embryo score leaves a child's future uncertain
Each embryo test needs a specific clinical question. A ranking also needs evidence about whether using it improves an outcome.
An embryo ranking estimates outcomes under a model. It leaves much of a future child's health outside the prediction.
Tests grouped under embryo screening answer different medical questions. One can investigate a known inherited condition. Another examines chromosome numbers, while a risk score estimates the probability of a later disease. Their results need interpretation according to the specific test.
Naming that test lets the discussion begin with the outcome it was designed to investigate. The evidence can then be assessed against the uncertainty left after the result.
PGT-M tests for a specified inherited condition
Preimplantation genetic testing takes place during IVF, after embryos are created outside the body. PGT-M tests for a particular monogenic inherited condition. HFEA, the UK's fertility regulator, describes its use for families with serious inherited conditions, distinguishing it from other embryo tests. HFEA's explanation of PGT-M
The condition defines the test's question. Future health problems outside that question remain outside what its result can assess.
Testing produces information used in selection. DNA editing changes genetic material. Detecting a variant can inform a decision about an embryo while leaving its genome unchanged.
The family's circumstances determine the test's clinical relevance. An explanation needs that context to show why the test is being considered for them.
PGT-A examines chromosome numbers
PGT-A investigates chromosome-number abnormalities. My earlier note described it as an established route to healthier families without accounting for the outcome evidence.
HFEA says randomized trials have not shown that routine PGT-A increases the chance of a baby for most IVF patients. Selection can also leave fewer embryos available for transfer. A reduction in miscarriage measures a different outcome from an increase in live births. HFEA's evidence summary
ASRM's committee opinion likewise says the value of routine screening for everyone undergoing IVF has not been demonstrated. The opinion examines possible differences between patient groups. Other questions remain unresolved. ASRM's committee opinion
A classification shows what the test found in a sample. Establishing that using the classification improves a patient's outcome requires an evaluation of that clinical use.
A polygenic score estimates risk
A polygenic risk score combines information from many genetic variants. NHGRI describes it as a statistical estimate based on genomic information. Environmental factors remain outside the score itself, leaving it as one part of assessing disease risk. NHGRI's definition
The resulting estimate applies a model across variants. A test for one particular inherited condition asks a different question. Numerical precision in the score leaves uncertainty about what will happen to an individual.
A lower predicted risk needs a reference group. It also needs a named condition over a defined period, with the model specified. Each detail affects what the comparison means.
A percentage alone can leave those details unstated. Interpreting the estimate comes before evaluating whether selecting according to its rank would help.
Embryo ranking needs clinical-outcome evidence
Applying polygenic scores to embryos is commonly called PGT-P. ASRM's 2026 ethics opinion calls the technology unproven, recommending that it should not currently be offered as a clinical service. It describes predictive limitations alongside genetic-environmental interactions, with IVF placing further limits on selection. ASRM's 2026 opinion
The available embryos limit any ranking. Producing scores leaves the number of embryos unchanged. The lowest-scoring embryo still faces the uncertainty of implantation before any possible live birth.
Demonstrating a calculation is therefore one stage. Clinical utility requires evidence about what happens when people act on the scores, including consequences of the selection process.
A company can sell a report before a long-term health outcome has been observed. That difference in timing creates an incentive to overstate control over the result. Assessing the claim requires examining the evidence without assigning the same motive to every clinician or researcher.
Keep the score within its purpose
A disease-risk estimate covers a limited medical prediction. A person's worth has no place in that measurement. Their relationships with other people also remain outside what an embryo score can describe.
Selecting an objective requires explaining why it should take precedence. The estimate will leave some effects unmeasured, with someone still responsible for choosing what to accept. An ordered display cannot make those decisions on its own.
The conversation needs a specific medical question, followed by the relevant evidence. Individual treatment choices require a clinical discussion that accounts for the family's circumstances.
Each genetic-testing claim needs to name its test with the outcome it can assess. Detecting a known condition supplies information for that question. A probability estimate leaves the child's eventual health uncertain.